Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.

Here's Why Investors Should Hold Elevance (ELV) Stock for Now

by Zacks Equity Research

Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.

Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Centene (CNC) Unveils its 2024 Projections: Key Takeaways

by Zacks Equity Research

Centene's (CNC) board boosts its share buyback program with a new $4 billion fund.

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.

HealthEquity (HQY) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended October 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

HealthEquity (HQY) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 22.45% and 2.29%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Curious about HealthEquity (HQY) Q3 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of HealthEquity (HQY) for the quarter ended October 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

What's in Store for Patterson Companies (PDCO) in Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.

Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Patterson Companies (PDCO) Partners With Pearl for AI Services

by Zacks Equity Research

Patterson Companies (PDCO) collaborates with dental AI solution provider, Pearl, to integrate the latter's Second Opinion software solution within its Eaglesoft software to deliver advanced solutions.

Embecta Corp. (EMBC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 40.48% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Masimo's (MASI) W1 Medical Watch to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.

Why You Should Add Integer Holdings (ITGR) to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

McKesson (MCK) Announces Availability of FDA-Cleared mCRC Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for mCRC.

Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales

by Zacks Equity Research

Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.

Are Medical Stocks Lagging HealthEquity (HQY) This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.